Objectives: This study employed proteomic profiling to identify specific tumor markers that might improveearly diagnosis of lung squamous cell carcinoma. Methods: Serum samples were isolated from 30 patients withstage I lung squamous cell carcinoma and 30 age-and gender-matched healthy controls, and proteomic profileswere obtained by matrix-assisted laser desorption ionization time of flight mass spectrometry. Results: Threehighly expressed potential tumor markers were identified in the sera of stage I lung squamous cell carcinomapatients, with molecular weights of 3261.69, 3192.07, and 2556.92 Da. One protein peak with molecular weight3261.69 Da was chosen as the candidate biomarker and identified as a fibrinogen alpha chain through a searchof the IPI, NCBI or SWISS-PROT protein databases. Conclusion: As a potential tumor biomarker, fibrinogenalpha chain may be applicable for the early diagnosis and prognosis of lung squamous cell carcinoma patients.
(2013). Proteomic Profiling of Serum from Stage I Lung Squamous Cell Carcinoma Patients. Asian Pacific Journal of Cancer Prevention, 14(4), 2273-2276.
MLA
. "Proteomic Profiling of Serum from Stage I Lung Squamous Cell Carcinoma Patients". Asian Pacific Journal of Cancer Prevention, 14, 4, 2013, 2273-2276.
HARVARD
(2013). 'Proteomic Profiling of Serum from Stage I Lung Squamous Cell Carcinoma Patients', Asian Pacific Journal of Cancer Prevention, 14(4), pp. 2273-2276.
VANCOUVER
Proteomic Profiling of Serum from Stage I Lung Squamous Cell Carcinoma Patients. Asian Pacific Journal of Cancer Prevention, 2013; 14(4): 2273-2276.